SCHEMBL25280765

SCHEMBL25280765

Nc1cc(CC(F)(F)F)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.57
▸ KDM4E B2RXH2 7/20 0.57
▸ HPGD P15428 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ CDC25B P30305 1/20 0.47
▸ CASP6 P55212 1/20 0.47
▸ RCE1 Q9Y256 1/20 0.47
▸ TDP1 Q9NUW8 5/20 0.44
▸ CYP3A4 P08684 3/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ PPM1B O75688 1/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ MAPT P10636 4/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ THRB P10828 3/20 0.42
▸ RECQL P46063 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ APEX1 P27695 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25279171 0.86 ALDH1A1 (0.66) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL19043821 0.82 EPHX2 (0.48) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL25229274 0.81 CFTR (0.61) ALDH1A1KDM4EHPGDHSD17B10ALOX15
SCHEMBL11693109 0.81 CFTR (0.42) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL27843215 0.81 PPARA (0.55) ALDH1A1KDM4EHPGDHSD17B10CASP6
SCHEMBL27416026 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL25173858 0.80 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL31118788 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL301452 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDHSD17B10CDC25B
SCHEMBL27860828 0.79 PTPN1 (0.42) ALDH1A1KDM4EHPGDHSD17B10CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
EP-4444313-A1 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
EP-4444300-A2 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed
WO-2023107696-A2 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed
CN-101155789-A 1H-quinazoline-2, 4-diones and their use as AMPA-receptor ligands NOVARTIS AG (CH) 2008-04-02 — — CN disclosed
CN-1863778-A Compounds and methods for treating dyslipidemia LILLY CO ELI (US) 2006-11-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 ALDH1A1 3650/4885KDM4E 136/4885HPGD 2981/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 ALDH1A1 3650/4885KDM4E 136/4885HPGD 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback